US Markets

Trump executive order to boost U.S. drug manufacturing -Navarro

Credit: REUTERS/JOSHUA ROBERTS

U.S. President Donald Trump on Thursday will sign an executive order aimed at boosting American drug manufacturing and lowering drug prices, White House trade adviser Peter Navarro said as the administration continues to grapple with the novel coronavirus outbreak.

WASHINGTON, Aug 6 (Reuters) - U.S. President Donald Trump on Thursday will sign an executive order aimed at boosting American drug manufacturing and lowering drug prices, White House trade adviser Peter Navarro said as the administration continues to grapple with the novel coronavirus outbreak.

The order, first reported by USA Today, "establishes Buy American rules for govt. agencies, strips away regulatory barriers to domestic pharmaceutical manufacturing, and catalyzes the Advanced Manufacturing technologies needed to keep drug prices low," Navarro tweeted.

It will allow the Department of Health and Human Services to use a 1950 law to procure certain "essential" medicines and other equipment from U.S. companies, although it does not list specific products, USA Today reported, citing the White House.

The order also directs the U.S. Food and Drug Administration and the Environmental Protection Agency to give priority status to U.S. drug ingredient manufacturers during their regulatory review process, and addresses counterfeit medicines sold by third-party sellers, according to the report.

So far, more than 157,000 people in the United States have died from COVID-19 - about 1,000 each day - with 4.8 million known COVID-19 cases. (Open https://tmsnrt.rs/2WTOZDR in an external browser for a Reuters interactive graphic)

Trump is expected to sign the order later on Thursday, USA Today said. The Republican president is scheduled to travel to Ohio to visit a Whirlpool manufacturing plant and hold a fundraiser for his re-election campaign before traveling to his New Jersey golf resort for the weekend, according to the White House.

Representatives for the White House did not immediately respond to a request for comment.

(Reporting by Susan Heavey; editing by Jonathan Oatis)

((202-898-8300; Reuters Messaging: susan.heavey.thomsonreuters.com@reuters.net))

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Latest Markets Videos

Reuters

Reuters, the news and media division of Thomson Reuters, is the world’s largest international multimedia news provider reaching more than one billion people every day. Reuters provides trusted business, financial, national, and international news to professionals via Thomson Reuters desktops, the world's media organizations, and directly to consumers at Reuters.com and via Reuters TV.

Learn More